Rani Therapeutics Hldgs Q2 EPS $(0.26) Beats $(0.32) Estimate
Portfolio Pulse from Benzinga Newsdesk
Rani Therapeutics Holdings (NASDAQ:RANI) reported a Q2 EPS loss of $(0.26), beating the analyst consensus estimate of $(0.32) by 18.75%. This represents a 29.73% improvement over the $(0.37) loss per share from the same period last year.
August 06, 2024 | 9:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rani Therapeutics Holdings reported a Q2 EPS loss of $(0.26), beating the analyst consensus estimate of $(0.32) by 18.75%. This is a significant improvement over the $(0.37) loss per share from the same period last year.
The better-than-expected EPS loss and significant year-over-year improvement are likely to positively impact RANI's stock price in the short term as it indicates better financial performance than anticipated.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100